Sigma-1 Receptor Agonists Modulate Endothelial Barrier Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments fail to effectively modulate endothelial barrier function, particularly in conditions involving impaired ATP metabolism, leading to issues like ischemia, sepsis, and edema, where endothelial cells rely more on glycolysis for energy production to spare oxygen for surrounding tissues.
Innovation Solution
Administration of sigma-1 receptor agonists, such as PRE-084, SA-4503, and afobazole, to enhance endothelial barrier function by shifting ATP production from oxidative mechanisms to anaerobic glycolysis, thereby stabilizing cellular energy and maintaining barrier integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If mitochondrial oxidative phosphorylation is used for ATP production in endothelial cells, then energy production efficiency is improved, but oxygen consumption increases and reactive oxygen species production occurs
Solution Approach 1:
The patent changes the metabolic parameter of endothelial cells by activating sigma-1 receptors to shift ATP production from oxidative phosphorylation to glycolysis. This parameter change reduces oxygen consumption and reactive oxygen species production while maintaining adequate ATP levels for barrier function.
Solution Approach 2:
The patent converts the typically harmful anaerobic glycolysis pathway into a beneficial alternative by activating it through sigma-1 receptor agonists. This allows endothelial cells to produce ATP without generating reactive oxygen species, effectively converting a less efficient pathway into a protective mechanism against oxidative stress.
2Object-affected harmful factors
If mitochondrial complex 3 is inhibited to reduce reactive oxygen species, then harmful factor production is reduced, but endothelial barrier function is disrupted
Solution Approach 1:
The patent introduces sigma-1 receptor agonists as intermediary substances that mediate between the need to reduce reactive oxygen species and the need to maintain barrier function. These agonists activate alternative metabolic pathways that preserve ATP production necessary for barrier integrity without relying on mitochondrial complex 3.
Solution Approach 2:
The patent applies sigma-1 receptor agonists as a preliminary protective measure before mitochondrial dysfunction occurs. This preliminary action shifts metabolism to glycolysis in advance, preventing the development of reactive oxygen species and maintaining barrier function under stress conditions.
3Object-affected harmful factors
If glycolysis is activated to spare oxygen for surrounding tissues, then oxygen availability to tissues is improved, but ATP production efficiency decreases
Solution Approach 1:
The patent changes the metabolic parameter of endothelial cells from oxidative phosphorylation to glycolysis by activating sigma-1 receptors. This parameter change reduces oxygen consumption by endothelial cells, thereby increasing oxygen availability to surrounding tissues while maintaining adequate ATP production through the glycolytic pathway.
Data Source
AI summary
Disclosed are compositions and methods for modulating endothelial barrier function.